Last10K.com

Acro Biomedical Co., Ltd. (ACBM) SEC Filing 10-Q Quarterly Report for the period ending Friday, June 30, 2023

SEC Filings

ACBM Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ACBM Annual Reports

ACBM Quarterly Reports

ACBM Corporate News

Acro Biomedical Co., Ltd.

HISTORY TOOLS
CIK: 1622996 Ticker: ACBM
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 14, 2023
Cover [Abstract]  
Entity Registrant NameACRO BIOMEDICAL CO., LTD. 
Entity Central Index Key0001622996 
Document Type10-Q 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Small Businesstrue 
Entity Shell Companyfalse 
Entity Emerging Growth Companyfalse 
Entity Current Reporting StatusYes 
Document Period End DateJun. 30, 2023 
Entity Filer CategoryNon-accelerated Filer 
Document Fiscal Period FocusQ2 
Document Fiscal Year Focus2023 
Entity Common Stock Shares Outstanding 60,042,000
Entity File Number000-55643 
Entity Incorporation State Country CodeNV 
Entity Tax Identification Number47-1950356 
Entity Address Address Line 112175 Visionary Way 
Entity Address Address Line 2Suite 1160 
Entity Address City Or TownFishers 
Entity Address State Or ProvinceIN 
Entity Address Postal Zip Code46038 
City Area Code317 
Local Phone Number286-6788 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity Interactive Data CurrentYes 

View differences made from one quarter to another to evaluate Acro Biomedical Co., Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acro Biomedical Co., Ltd..

Continue

Assess how Acro Biomedical Co., Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acro Biomedical Co., Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue